273 related articles for article (PubMed ID: 26169045)
1. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.
Pantuck AJ; Pettaway CA; Dreicer R; Corman J; Katz A; Ho A; Aronson W; Clark W; Simmons G; Heber D
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):242-8. PubMed ID: 26169045
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.
Paller CJ; Ye X; Wozniak PJ; Gillespie BK; Sieber PR; Greengold RH; Stockton BR; Hertzman BL; Efros MD; Roper RP; Liker HR; Carducci MA
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):50-5. PubMed ID: 22689129
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.
Pantuck AJ; Leppert JT; Zomorodian N; Aronson W; Hong J; Barnard RJ; Seeram N; Liker H; Wang H; Elashoff R; Heber D; Aviram M; Ignarro L; Belldegrun A
Clin Cancer Res; 2006 Jul; 12(13):4018-26. PubMed ID: 16818701
[TBL] [Abstract][Full Text] [Related]
4. A review of pomegranate in prostate cancer.
Paller CJ; Pantuck A; Carducci MA
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):265-270. PubMed ID: 28440320
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
Smith MR; Manola J; Kaufman DS; George D; Oh WK; Mueller E; Slovin S; Spiegelman B; Small E; Kantoff PW
Cancer; 2004 Oct; 101(7):1569-74. PubMed ID: 15468186
[TBL] [Abstract][Full Text] [Related]
6. Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.
Paller CJ; Zhou XC; Heath EI; Taplin ME; Mayer T; Stein MN; Bubley GJ; Pili R; Hudson T; Kakarla R; Abbas MM; Anders NM; Dowling D; King S; Bruns AB; Wagner WD; Drake CG; Antonarakis ES; Eisenberger MA; Denmeade SR; Rudek MA; Rosner GL; Carducci MA
Clin Cancer Res; 2018 Jan; 24(2):306-315. PubMed ID: 29113986
[No Abstract] [Full Text] [Related]
7. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
Smith MR; Manola J; Kaufman DS; Oh WK; Bubley GJ; Kantoff PW
J Clin Oncol; 2006 Jun; 24(18):2723-8. PubMed ID: 16782912
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
9. A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer.
van Die MD; Williams SG; Emery J; Bone KM; Taylor JM; Lusk E; Pirotta MV
Prostate; 2017 May; 77(7):765-775. PubMed ID: 28181675
[TBL] [Abstract][Full Text] [Related]
10. A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance.
Jarrard D; Filon M; Huang W; Havighurst T; DeShong K; Kim K; Konety BR; Saltzstein D; Mukhtar H; Wollmer B; Suen C; House MG; Parnes HL; Bailey HH
Prostate; 2021 Jan; 81(1):41-49. PubMed ID: 33095939
[TBL] [Abstract][Full Text] [Related]
11. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Smith MR; Saad F; Oudard S; Shore N; Fizazi K; Sieber P; Tombal B; Damiao R; Marx G; Miller K; Van Veldhuizen P; Morote J; Ye Z; Dansey R; Goessl C
J Clin Oncol; 2013 Oct; 31(30):3800-6. PubMed ID: 24043751
[TBL] [Abstract][Full Text] [Related]
12. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
13. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.
Paller CJ; Olatoye D; Xie S; Zhou X; Denmeade SR; Eisenberger MA; Antonarakis ES; Carducci MA; Rosner GL
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):28-33. PubMed ID: 24100642
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.
Paller CJ; Rudek MA; Zhou XC; Wagner WD; Hudson TS; Anders N; Hammers HJ; Dowling D; King S; Antonarakis ES; Drake CG; Eisenberger MA; Denmeade SR; Rosner GL; Carducci MA
Prostate; 2015 Oct; 75(14):1518-25. PubMed ID: 26012728
[TBL] [Abstract][Full Text] [Related]
15. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation.
Choi YH; Han DH; Kim SW; Kim MJ; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY
Prostate; 2019 May; 79(6):614-621. PubMed ID: 30671976
[TBL] [Abstract][Full Text] [Related]
17. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Daskivich TJ; Regan MM; Oh WK
Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.
Marschner N; Rüttinger D; Zugmaier G; Nemere G; Lehmann J; Obrist P; Baeuerle PA; Wolf A; Schmidt M; Abrahamsson PA; Reinhardt C; Heidenreich A
Urol Int; 2010; 85(4):386-95. PubMed ID: 20606402
[TBL] [Abstract][Full Text] [Related]
19. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
[TBL] [Abstract][Full Text] [Related]
20. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.
Khatami A; Aus G; Damber JE; Lilja H; Lodding P; Hugosson J
Int J Cancer; 2007 Jan; 120(1):170-4. PubMed ID: 17013897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
